Nisa Investment Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-2
Closed -$35 – 2939
2024
Q1
$35 Sell
2
-1
-33% -$18 ﹤0.01% 2758
2023
Q4
$41 Sell
3
-29
-91% -$676 ﹤0.01% 2634
2023
Q3
$1.19K Buy
32
+3
+10% +$134 ﹤0.01% 2372
2023
Q2
$1.16K Sell
29
-29
-50% -$1.64K ﹤0.01% 2418
2023
Q1
$4K Sell
58
-116
-67% -$11.3K ﹤0.01% 2253
2022
Q4
$14K Sell
174
-84
-33% -$8.75K ﹤0.01% 2129
2022
Q3
$28K Buy
258
+232
+892% +$26.1K ﹤0.01% 1950
2022
Q2
$5K Hold
26
– – ﹤0.01% 2266
2022
Q1
$6K Buy
+26
New +$8.28K ﹤0.01% 2277
2021
Q4
– Sell
-185
Closed -$83K – 2209
2021
Q3
$83K Hold
185
– – ﹤0.01% 1780
2021
Q2
$72K Hold
185
– – ﹤0.01% 1833
2021
Q1
$66K Hold
185
– – ﹤0.01% 1921
2020
Q4
$91K Buy
185
+158
+585% +$72.9K ﹤0.01% 1770
2020
Q3
$9K Buy
27
+10
+59% +$3.4K ﹤0.01% 2128
2020
Q2
$6K Hold
17
– – ﹤0.01% 1990
2020
Q1
$4K Buy
17
+8
+89% +$2.54K ﹤0.01% 1967
2019
Q4
$4K Hold
9
– – ﹤0.01% 1941
2019
Q3
$3K Hold
9
– – ﹤0.01% 1950
2019
Q2
$5K Hold
9
– – ﹤0.01% 1888
2019
Q1
$9K Hold
9
– – ﹤0.01% 1774
2018
Q4
$8K Hold
9
– – ﹤0.01% 1691
2018
Q3
$10K Buy
+9
New +$8.8K ﹤0.01% 1719

Other funds holding ATRA

Nisa Investment Advisors's ATRA Position: Q2 2024 in Review

Nisa Investment Advisors sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 2 shares — an estimated $35 sold.

Nisa Investment Advisors first reported a position in ATRA in Q3 2018 and held it in 22 quarters. The position peaked at $91K in Q4 2020. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

  • Nisa Investment Advisors reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Nisa Investment Advisors sold 2 Atara Biotherapeutics shares in Q2 2024, an estimated $35.
  • Nisa Investment Advisors first reported a position in Atara Biotherapeutics in Q3 2018 and held it in 22 quarters.
  • Nisa Investment Advisors's Atara Biotherapeutics position peaked at $91K in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on Nisa Investment Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.